Intravitreal triamcinolone for the treatment of diabetic macular edema

Current Diabetes Reviews

Volumn 2, Issue 1, 2006, Pages 99-112

  Gómez Ulla, Francisco ^a,b,d   Marticorena, Joaquín ^a   Alfaro III, D Virgil ^c   Fernández, Maribel ^b   Rodríguez Méndez, Elizabeth ^b   Rothen, Michelle ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Fundación Instituto Gallego de Oftalmología   (Spain)

^c St Francis Health System   (United States)

^d HOSPITAL DE CONXO   (Spain)

Author keywords

Diabetic macular edema; Intravitreal triamcinolone

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; CIPROFLOXACIN; CORTICOSTEROID; GLUCOCORTICOID; HYDROCORTISONE; KENACORT 40; MINERALOCORTICOID; PLACEBO; POVIDONE IODINE; PREDNISOLONE; PROTEIN KINASE C INHIBITOR; SOMATOSTATIN DERIVATIVE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BLEPHARITIS; BLURRED VISION; CATARACT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONJUNCTIVITIS; CORNEA OPACITY; CORNEA ULCER; CRYSTAL STRUCTURE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE PAIN; EYE TOXICITY; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; HYPOPYON; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; LACRIMAL DUCT OCCLUSION; LASER COAGULATION; NONHUMAN; PHOTOPHOBIA; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FOVEA; RETREATMENT; REVIEW; TREATMENT FAILURE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

ANTI-INFLAMMATORY AGENTS; DIABETIC RETINOPATHY; HALF-LIFE; HUMANS; LASER COAGULATION; MACULAR EDEMA; TRIAMCINOLONE; VITREOUS BODY;

EID: 33746155329     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339906775473572     Document Type: Review

References (96)

1. Ferris FL III, Patz A. Macular Emma. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28: S 452-61.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 12: 1464-74.
3. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 10: 1594-602.
4. Early Treatment Diabetic Retinopathy Study research group.Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 12: 1796-06.
5. Early Treatment Diabetic Retinopathy Study research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766-85.
6. Bresnick GH. Diabetic macular edema. A review. Ophthalmology 1986; 7: 989-97.
7. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 5: 753-59.
8. Donnelly R, Idris I, Forrester JV. Proteinkinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004; 88: 145-51.
9. Clemens A, Klevesath MS, Hofmann M, et al. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfuncion in patients with diabetes mellitus.Metabolism 1999; 48: 1236-40.
10. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 5: 920-27.
11. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 1: 57-61.
12. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 2: 218-24.
13. Ciardella AP, Klancnik J, Schilth W, Barile G, Chang S. Intravitreal traimcinolone for the treatment of refractory diabetic macular edema with hard exudates: an optical coherence tomography study. Br J ophthalmol 2004; 88: 1131-36.
14. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Three-month efficacy and safety results of a prospective, randomized, doubled-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111: 2044-49.
15. Ruhmann A.G., Berliner D.L. Effect of steroids on growth of mouse fibroblasts in vitro. Endocrinology 1965; 76: 916-27.
16. Rozen, V, Chernin L. Effect of different doses of glucocorticoids on growth of monolayer cultures of connective tissue. Fed Proc 1974; 24: 861.
17. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferation with intravitreal steroids. Tr Am Ophth Soc 1979; 77: 177-8.
18. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980; 1: 131-6.
19. Tano Y, Chandler DB, McCuen BW, Machemer R. Glucocorticosteroid inhibition of intraocular proliferation after injury. Am J Ophthalmol 1981; 2: 184-9.
20. Goodman y Gilman. Las bases farmacológicas de la terapéutica. Décima ed. México, D.F.: McGraw-Gill Interamericana; 2003.
21. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980; 6: 810-16.
22. Isbibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 5: 708-11.
23. Ciulla TA, Criswell MH, Danis RP, et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol 2003; 8: 1032-37.
24. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 3: 399-04.
25. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993; 1: 34-40.
26. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 12: 2099-104.
27. Perry HT, Cohn BT, NAuheim JS. Accidental intraocular injection with a Dermojet syringe. Arch Dermatol 1977; 8: 1131.
28. Gómez-Ulla F, Gonzalez F, Ruiz-Fraga C. Unintentional intraocular injection of corticosteroids. Acta Ophthalmol (Copenh) 1993; 3: 419-21.
29. Dominguez A, Quiroga P, Jareño M. El tratamiento de enfermedades médicas con triamcinolona intravítrea. Arch Soc Esp Oftalmol 1993; 65: 491-8.
30. Dominguez Collazo A. Devices and drugs introduced intraocularly for the treatment of eye diseases "in the office". An R Acad Nac Med (Madr) 1994; 2: 377-5.
31. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 1995; 4: 293-8.
32. Doukas J, Hechtinan HB, Shepro D. Endothelial-secret arachinodic metabolites modulate polymorphonucear leukocyte chemotaxis and diapedesis in vitro. Blood 1988; 71: 771-9.
33. Thach A, Dugel P, Findall R, Sipperley J, Sneed S. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to typical medications. Ophthalmology 1997; 104: 2003-8.
34. Aiello LP, Bursell SE, Clermont A, et al. Vascular endotelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppresed by an orally effective β-isoform-selective inhibitor. Diabetes. 1997; 46: 1473-80.
35. Antonetti D, Barber A, Holliger L, Wolpert E, Gardner T. Vascular endothelial growth induces rapid phosphorylation of tight junction proteins occluding and zonular occluden. J Bio Chem 1999; 274: 23463-7.
36. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985; 10: 1567-9.
37. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982; 4: 415-7.
38. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 4: 681-6.
39. Jonas JB. Intraccular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004; 3: 560-2.
40. Hormones and synthetic substitutes. In: Mc Evoy G, ed. AHFS Drug information. Bethesda: American Society of Health-System Pharmacists; 2003: 2896-7.
41. Farmacopea Española. Segunda ed. Madrid: Secretaría General Técnica.; 2002: 2457-8.
42. McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 6: 785-8.
43. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986; 2: 190-5.
44. Brown WJ, Buist NR, Gipson HT, Huston RK, Kennaway NG. Fatal benzyl alcohol poisoning in a neonatal intensive care unit. Lancet 1982; 1: 1250.
45. Jonas JB and Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425-7.
46. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003; 4: 462-8.
47. Rodríguez-Coleman H, Luang P, Kim H, et al. Intravitreal injection of triamcinolone for diffuse macular edeam. Arch Ophthalmol 2004; 122: 1085-6.
48. Nishimura A, Kobayashi A, Segawa Y, et al. Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 2003; 6: 777-9.
49. Marticorena J, Gómez-Ulla F, Quezada E. In: Domínguez A, Gómez-Ulla F, Ruiz JM, Benitez del Castillo JM, Abecia E. Antiinflamatorios y antiangiogénicos intraoculares. Sociedad Española de Oftalmología. Madrid. 2004; 115-27.
50. Jonas JB, Hayler JK, Panda-Jones S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graefe's Arch Clin Exp Ophthalmol 2001; 239: 464-5.
51. Jonas JB, Hayler JK, Panda-Jones S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064-7.
52. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa, JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 8: 1155-9.
53. Hernáez-Ortega MC, Soto-Pedre E. A simple and rapid method for purification of triamcinolone acetónido suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 2004; 35: 350-1.
54. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004; 24(5 Suppl): S3-19.
55. Jonas JB and Degenring RF. Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema. Klin Monatsbl Augenheilkd 2002; 219: 429-32.
56. Degenring RF, Kreissig I, Jonas JB. Intraocular triamcinolone for difusse diabetic macular edema. Ophthalmologe 2004; 10: 113-20.
57. Jonas JB, Harder B, Kamppeter BA. Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004; 138: 970-7.
58. Jonas JB, Kreissig I, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158-60.
59. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye 2005; 19: 747-51. Published Online First: 10 September 2004. doi:10.108/sj.eye.6701636.
60. Krepler K, Wagner J, Sacu S, Wedrich A. The effect of intravitreal triamcinolone on diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2005; 243: 478-81. Published Online First: 7 December 2004. doi:10.1007/s00417-004-1059-8.
61. Ozkiris A, Evereklioglu C, Erkilic K, Tamcelik N, Mirza E. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004; 14: 543-9.
62. Lam DS, Chan CK, Tang EW, Li KK, Fan DS, Chan WM. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Experiment Ophthalmol 2004; 32: 569-72.
63. Micelli Ferrari T, Shorgia L, Furino C, Cardascia N, Ferreri P, Besozzi G, Sborgia C. Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema. Eur J Ophthalmol 2004; 14: 321-4.
64. Ozkiris A, Evereklioglu C, Oner A, Erkilic K. Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema. Doc Ophthalmol 2004; 109: 139-45.
65. Islam MS, Negi A, Vernon SA. Improved visual acuity and macular thickness 1 week after intravitreal triamcinolone for diabetic macular oedema. Eye. Published Online First: 3 December 2004. doi:10.1038/ sj.eye.6701766.
66. Bakri SJ, Beer PM. Intravitreal triamcinolone injection for diabetic maculur edema: a clinical and fluorescein angiographic case series. Can J Ophthalmol 2004; 39: 755-60.
67. Gómez-Ulla F, Marticorena J, Fernández M, Rodríguez Cid MJ. Tratamiento del edema macular diabético persistente con triamcinolona intravítrea. In: Domínguez A, Gómez-Ulla F, Ruiz JM, et al. eds. Antiinflamatorios y antiangiogénicos intraoculares. Madrid. Sociedad Española de Oftalmología; 2004: 83-92.
68. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 3: 244-50.
69. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 2: 218-22.
70. Gillies MC, Simpson JK Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 5: 667-73.
71. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002; 5: 527-9.
72. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 8: 1517-25.
73. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 3: 344-7.
74. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 3: 419-25.
75. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004; 4: 758-60.
76. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003; 2: 384-6.
77. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB. Safety of an intravitical injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 3: 336-40.
78. Bakri S, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003; 34: 386-90.
79. Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2004; 2: 184-5.
80. Jonas JB, Kreissig I, Degenring R. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 2003; 121: 729-30.
81. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995; 1: 55-64.
82. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998; 4: 277-81.
83. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 3: 344-7.
84. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 8: 1517-25.
85. Cibis W, Abdel-Latif A, Bron A, et al. Fundamentals and Principles of Ophthalmology, In: Basic and Clinical Science Course 2001-2002. San Francisco: The foundation of the American Academy of Ophthalmology; 2001; II: 424.
86. Chylack LT Jr, Wolfe JK, Singer DK et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993; 111(6): 831-6.
87. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthatmitis after intravitreal triamcinolone acetonide injection. Retina 2003; 5: 686-91.
88. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 5: 791-6.
89. Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CW. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003; 2: 271-3.
90. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003; 11: 1663-4.
91. Eifrig CW, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers 2002; 5: 373-8.
92. Cohen SM, Flynn HW Jr, Murray TG, Smiddy WE. Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group. Ophthalmology 1995; 5: 705-12.
93. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003; 8: 972-4.
94. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003, 9: 1279-82.
95. Antonetti DA, Wolpert EB, DeMaio L, et al. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased phosphorilation of occludin. J Neurochem 2002; 80: 667-70
96. Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 2003; 3: 361.2